Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing

R. M. Lloyd, D. A. Burns, J. T. Huong, R. L. Mathis, M. A. Winters, M. Tanner, A. De La Rosa, B. Yen-Lieberman, W. Armstrong, A. Taege, D. R. McClernon, J. L. Wetshtein, Brian M. Friedrich, Monique Ferguson, William O'Brien, P. M. Feorino, M. Holodniy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.

Original languageEnglish (US)
Pages (from-to)1491-1496
Number of pages6
JournalJournal of Clinical Microbiology
Volume47
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Hepacivirus
HIV-1
HIV
Viral Load
Genotype
Edetic Acid
Buffers
Nucleotides
Clinical Trials
Technology
Amino Acids
Costs and Cost Analysis
Mutation

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. / Lloyd, R. M.; Burns, D. A.; Huong, J. T.; Mathis, R. L.; Winters, M. A.; Tanner, M.; De La Rosa, A.; Yen-Lieberman, B.; Armstrong, W.; Taege, A.; McClernon, D. R.; Wetshtein, J. L.; Friedrich, Brian M.; Ferguson, Monique; O'Brien, William; Feorino, P. M.; Holodniy, M.

In: Journal of Clinical Microbiology, Vol. 47, No. 5, 05.2009, p. 1491-1496.

Research output: Contribution to journalArticle

Lloyd, RM, Burns, DA, Huong, JT, Mathis, RL, Winters, MA, Tanner, M, De La Rosa, A, Yen-Lieberman, B, Armstrong, W, Taege, A, McClernon, DR, Wetshtein, JL, Friedrich, BM, Ferguson, M, O'Brien, W, Feorino, PM & Holodniy, M 2009, 'Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing', Journal of Clinical Microbiology, vol. 47, no. 5, pp. 1491-1496. https://doi.org/10.1128/JCM.02354-08
Lloyd, R. M. ; Burns, D. A. ; Huong, J. T. ; Mathis, R. L. ; Winters, M. A. ; Tanner, M. ; De La Rosa, A. ; Yen-Lieberman, B. ; Armstrong, W. ; Taege, A. ; McClernon, D. R. ; Wetshtein, J. L. ; Friedrich, Brian M. ; Ferguson, Monique ; O'Brien, William ; Feorino, P. M. ; Holodniy, M. / Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. In: Journal of Clinical Microbiology. 2009 ; Vol. 47, No. 5. pp. 1491-1496.
@article{a927bfe36e674c04bc1fb5319c42caa1,
title = "Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing",
abstract = "A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99{\%} concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.",
author = "Lloyd, {R. M.} and Burns, {D. A.} and Huong, {J. T.} and Mathis, {R. L.} and Winters, {M. A.} and M. Tanner and {De La Rosa}, A. and B. Yen-Lieberman and W. Armstrong and A. Taege and McClernon, {D. R.} and Wetshtein, {J. L.} and Friedrich, {Brian M.} and Monique Ferguson and William O'Brien and Feorino, {P. M.} and M. Holodniy",
year = "2009",
month = "5",
doi = "10.1128/JCM.02354-08",
language = "English (US)",
volume = "47",
pages = "1491--1496",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing

AU - Lloyd, R. M.

AU - Burns, D. A.

AU - Huong, J. T.

AU - Mathis, R. L.

AU - Winters, M. A.

AU - Tanner, M.

AU - De La Rosa, A.

AU - Yen-Lieberman, B.

AU - Armstrong, W.

AU - Taege, A.

AU - McClernon, D. R.

AU - Wetshtein, J. L.

AU - Friedrich, Brian M.

AU - Ferguson, Monique

AU - O'Brien, William

AU - Feorino, P. M.

AU - Holodniy, M.

PY - 2009/5

Y1 - 2009/5

N2 - A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.

AB - A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.

UR - http://www.scopus.com/inward/record.url?scp=66149146560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149146560&partnerID=8YFLogxK

U2 - 10.1128/JCM.02354-08

DO - 10.1128/JCM.02354-08

M3 - Article

VL - 47

SP - 1491

EP - 1496

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 5

ER -